CT-RECIST-Response-Indicator

CT RECIST response, as measured by the change of tumor diameter, can accurately reflect objective response rate for advanced NSCLC patients. However, there exists obvious discordant between CT RECIST response and prognostic indicators. Thus, our study aimed to identify a new CT RECIST response indicator at the early treatment stage to reflect the prognosis more accurately.We studied 916 tumor lesions obtained through deep learning and found that the shape of the lesions was irregular. Besides, we found inconsistencies in CT RECIST responses as measured by changes of tumor diameter and volume at the early treatment stage (response in and ). Moreover, the response in exhibited greater consistency with pathological response and showed a statistical significance with overall survival (P-value=0.0093). In conclusion, our study suggests that response in may serve as a new prognostic indicator for NSCLC patients receiving immunotherapy combined with chemotherapy or chemotherapy alone.

CT RECIST响应，即通过肿瘤直径的变化所测得，能够精确反映晚期非小细胞肺癌患者的客观缓解率。然而，CT RECIST响应与预后指标之间存在显著的分歧。因此，本研究旨在识别一个早期治疗阶段的新的CT RECIST响应指标，以更准确地反映预后。我们研究了通过深度学习获得的916个肿瘤病灶，发现病灶的形状不规则。此外，我们还发现在早期治疗阶段，通过肿瘤直径和体积的变化所测得的CT RECIST响应存在不一致性（响应在）。而且，响应在与病理反应的一致性更高，并且与总生存率存在显著的统计学关联（P值=0.0093）。总之，本研究表明，响应在可能作为免疫疗法联合化疗或单独化疗的非小细胞肺癌患者的新的预后指标。